Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers

T. L. Chen, G. B. Vogelsang, B. G. Petty, R. B. Brundrett, D. A. Noe, G. W. Santos, O. M. Colvin

Research output: Contribution to journalArticlepeer-review

Abstract

The plasma pharmacokinetics and urinary excretion of thalidomide have been evaluated in eight healthy male volunteers receiving a single oral dose of 200 mg. Concentrations of thalidomide were determined by a new HPLC assay. Plasma concentration vs. time data were well fit by a one-compartment model. The mean (± SD) peak concentration, 1.15 ± 0.2 μg/ml, was achieved at 4.39 ± 1.27 hr. Absorption and elimination half-lives were 1.70 ± 1.05 hr and 8.70 ± 4.11 hr, respectively, with a lag time of 0.41 ± 0.17 hr observed in six subjects. The apparent volume of distribution and total body clearance rate, based on assumed complete bioavailability, were 120.69 ± 45.36 liters and 10.41 ± 2.04 liters/hr. The urinary excretion of thalidomide accounted for only 0.6 ± 0.22% of the total dose administered over 24 hr, and the renal clearance rate was 0.08 ± 0.03 liter/hr. This suggests that the major route of elimination of thalidomide is nonrenal.

Original languageEnglish (US)
Pages (from-to)402-405
Number of pages4
JournalDrug Metabolism and Disposition
Volume17
Issue number4
StatePublished - 1989

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers'. Together they form a unique fingerprint.

Cite this